Cargando…

1687. Omadacycline in Female Adults With Acute Pyelonephritis: Results from a Randomized, Double-Blind, Adaptive Phase 2 Study

BACKGROUND: Omadacycline (OMC) is a novel intravenous (IV) and oral aminomethylcycline, approved in the USA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in adults. We present data from a randomized, adaptive dose–response phase 2 study of OMC in a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Overcash, J Scott, Tzanis, Evan, Manley, Amy, Kirsch, Courtney, Serio, Alisa W, White, Tiffany, Wright, Kelly, Chitra, Surya, Eckburg, Paul B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777848/ http://dx.doi.org/10.1093/ofid/ofaa439.1865

Ejemplares similares

1688. Omadacycline in Female Adults With Cystitis: Results From a Randomized, Double-Blinded, Adaptive Phase 2 Study
por: Overcash, J Scott, et al.
Publicado: (2020)

Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1b Study
por: Overcash, J. Scott, et al.
Publicado: (2019)

Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function
por: Berg, Jolene K., et al.
Publicado: (2018)

Efficacy of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by Disease Severity: Results From the OPTIC Study
por: Ramirez, Julio, et al.
Publicado: (2021)

Omadacycline for Acute Bacterial Skin and Skin Structure Infections
por: Abrahamian, Fredrick M, et al.
Publicado: (2019)

Safety and Pharmacokinetics of the Aminomethylcycline Antibiotic Omadacycline Administered to Healthy Subjects in Oral Multiple-Dose Regimens
por: Bundrant, Lu Ann, et al.
Publicado: (2018)

734. Modeling the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Omadacycline with and without a Loading Dose
por: Friedrich, Lawrence, et al.
Publicado: (2019)

1347. Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials
por: Abrahamian, Fredrick M, et al.
Publicado: (2018)

Effect of Food on the Bioavailability of Omadacycline in Healthy Participants
por: Tzanis, Evan, et al.
Publicado: (2016)

The Effect of Verapamil, a P-gp Inhibitor, on the Pharmacokinetics, Safety, and Tolerability of Omadacycline in Healthy Adults: A Phase I, Open-Label, Single-Sequence Study
por: Hunt, Thomas L., et al.
Publicado: (2020)

Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects
por: Gotfried, Mark H., et al.
Publicado: (2017)

An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline Antibiotic
por: Opal, Steven, et al.
Publicado: (2019)

Activity of Omadacycline in Rat Methicillin-Resistant Staphylococcus aureus Osteomyelitis
por: Karau, Melissa J., et al.
Publicado: (2022)

1374. Integrated Safety Summary of Omadacycline: A Novel Aminomethylcycline Antibiotic
por: Opal, Steven, et al.
Publicado: (2018)

1356. Improvement in Quality of Life for Adults With Acute Bacterial Skin and Skin Structure Infections Following Treatment With Omadacycline or Linezolid
por: Tzanis, Evan, et al.
Publicado: (2018)

Potency of Omadacycline against Mycobacteroides abscessus Clinical Isolates In Vitro and in a Mouse Model of Pulmonary Infection
por: Nicklas, Danielle A., et al.
Publicado: (2022)

Clinical Efficacy of Patients With Secondary Bacteremia Treated With Omadacycline: Results From Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies
por: Sakoulas, George, et al.
Publicado: (2021)

Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Omadacycline on QT/QTc Intervals in Healthy Subjects
por: Darpo, Borje, et al.
Publicado: (2019)

110. Clinical Outcomes of Patients with Secondary Bacteremia in the Omadacycline Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies
por: Sakoulas, George, et al.
Publicado: (2019)

1202. Subinhibitory Concentrations of Omadacycline Inhibit Staphylococcus aureus Hemolytic Activity in Vitro
por: Serio, Alisa W, et al.
Publicado: (2020)

Sub-growth-inhibitory concentrations of omadacycline inhibit Staphylococcus aureus haemolytic activity in vitro
por: Serio, Alisa W, et al.
Publicado: (2021)

1208. Omadacycline In Vitro Activity Against Bacillus Anthracis
por: Serio, Alisa W, et al.
Publicado: (2021)

Early Clinical Response in Community-acquired Bacterial Pneumonia: From Clinical Endpoint to Clinical Practice
por: Ramirez, Julio A, et al.
Publicado: (2019)

Omadacycline and Clostridioides difficile: A Systematic Review of Preclinical and Clinical Evidence
por: Garey, Kevin W., et al.
Publicado: (2022)

Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data
por: Lakota, Elizabeth A., et al.
Publicado: (2020)

The evolution of dynamics vibration theory from 1687 to 1742
por: Cannon, John T, et al.
Publicado: (1981)

P1687: THROMBOEMBOLISM IN COVID-19 PATIENTS ON ECMO
por: Jones, C., et al.
Publicado: (2022)

Evaluation of the Impact of Comorbidities on Omadacycline Pharmacokinetics
por: Trang, M., et al.
Publicado: (2023)

Omadacycline in the treatment of community-acquired bacterial pneumonia in patients with comorbidities: a post-hoc analysis of the phase 3 OPTIC trial
por: Rodriguez, George D., et al.
Publicado: (2023)

700. Safety and Efficacy of Omadacycline in Patients with Diabetes in Phase 3 Clinical Studies
por: Pai, Manjunath P, et al.
Publicado: (2019)

1492. Targeted Substitution of Omadacycline in Place of Standard of Care for CABP Treatment is Associated with a Risk Reduction of Clostridioides difficile Infection and Financial Cost Savings in the Acute Care Setting
por: Rodriguez, Mauricio, et al.
Publicado: (2020)

Efficacy and Safety of Omadacycline Versus Linezolid in Acute Bacterial Skin and Skin Structure Infections in Persons Who Inject Drugs
por: Moran, Gregory J., et al.
Publicado: (2022)

Paper bodies: a catalogue of anatomical fugitive sheets 1538-1687.
por: Carlino, A.
Publicado: (1999)

Health-Related Quality of Life as Measured by the 36-Item Short Form Survey Among Adults With Acute Bacterial Skin and Skin Structure Infections who Received Either Omadacycline or Linezolid in a Phase 3 Double-Blind, Double-Dummy Clinical Trial
por: Chitra, Surya, et al.
Publicado: (2021)

Efficacy of Omadacycline-Containing Regimen in a Mouse Model of Pulmonary Mycobacteroides abscessus Disease
por: Rimal, Binayak, et al.
Publicado: (2023)

1561. Omadacycline Pharmacokinetics: Influence of Mortality Risk Score Among Patients with Community-Acquired Bacterial Pneumonia
por: Lakota, Elizabeth A, et al.
Publicado: (2019)

Safety and efficacy of omadacycline by BMI categories and diabetes history in two Phase III randomized studies of patients with acute bacterial skin and skin structure infections
por: Pai, Manjunath P, et al.
Publicado: (2021)

Omadacycline: a novel aminomethylcycline
por: Burgos, Rodrigo M, et al.
Publicado: (2019)

Omadacycline: A Modernized Tetracycline
por: Gallagher, Jason C
Publicado: (2019)

Microbiology and Preclinical Review of Omadacycline
por: Karlowsky, James A, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h4infvc7rcs38nsntdi8dng08a